Rocket Pharma stock upgraded at Goldman Sachs (RCKT:NASDAQ)
· seekingalpha.com
Rocket Pharma (RCKT) stock gains as Goldman Sachs upgrades the firm, citing RP-A501, its experimental therapy for a rare disorder called Danon disease. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...